LUCAS acknowledged as a beneficial tool for solving emergency situations in the cath lab at the TCT world congress in Washington
31st of October 2007, Lund, Sweden
During the TCT (Transcatheter Cardiovascular Therapeutics) congress which took place last week in Washington D.C., US, the LUCAS Chest Compression System was recognized as a beneficial and applicable tool for acute and therapy resistant cardiac arrest in the catheterization laboratory. Under the title “Greatest Cases from Around the World; The Winners of the Most Challenging Case Competition” , Dr. GK Olivecrona from Lund University Hospital, Lund, Sweden, presented a case where LUCAS sustained blood circulation on a cardiac arrest patient during 55 minutes of continued interventional procedure. The patient was rescued; the heart function restored and six months later, the patient is living an active life with intact neurological status.
Erik von Schenck, CEO of JOLIFE says; “We are excited by the very positive response on LUCAS that was expressed by a panel of some of the world’s leading interventional cardiologists. LUCAS clearly solves a dilemma and helps save cardiac arrest patients by enabling simultaneous interventional therapy. This facilitates the treatment of the cause of the arrest in the catheterization laboratory. Manual cardiopulmonary resuscitation, the alternative to LUCAS chest compressions, is exceedingly difficult to perform effectively, safely and over a longer period of time.”
The TCT congress – one of the world’s most important congresses for interventional cardiologists – is a yearly event. This year more than 6000 interventional cardiologists from all over the world were gathered to listen to the latest developments within catheter based interventional cardiology. LUCAS was presented at three different case lectures, acknowledging its applicability and benefits in the catheterization laboratory.
During interventional treatment of patients with myocardial infarction unexpected complications sometimes occur that lead to sudden cardiac arrest during the procedure. The situation is critical with acute loss of blood pressure and circulation. The provision of effective and uninterrupted cardiopulmonary resuscitation is key for oxygenation of the brain, but associated with practical difficulties as well as risks for the caregiver. The caregiver either has to interrupt compressions frequently – resulting in loss of oxygenation of the patient’s brain and heart – or expose him/herself to X-ray during the continued interventional procedure. LUCAS Chest Compression System is partly radiolucent and allows for continued intervention during simultaneous mechanical compressions without personnel having to be directly exposed to X-ray. This facilitates the restoration of the coronary circulation and spontaneous heart rhythm.
About coronary interventions
PCI (percutaneous coronary intervention) or coronary angioplasty, is an invasive therapeutic procedure to treat the narrowed or completely obstructed coronary arteries of the heart. These obstructions or blockages are due to cardiovascular disease. The symptoms are either heart pain or heart attack. By insertion of a catheter based balloon through a small incision in the artery in the groin, the coronary arteries are accessed and the obstructions are opened up by balloon inflation. This allows for improved blood flow in the coronary arteries.
About LUCAS™ CPR
The LUCAS™ Chest Compression System assists ambulance and hospital professionals in saving cardiac arrest victims by providing continuous compressions, which helps sustain blood flow to the brain and heart. The AHA/ERC guidelines from 2005 emphasize effective and uninterrupted chest compressions before defibrillation. LUCAS provides chest compressions in adherence with the guidelines without rescuer fatigue or variations in quality. The device enables safe transportation and allows for simultaneous defibrillation and angioplasty.
About JOLIFE AB
JOLIFE is dedicated to increasing the survival rates related to sudden cardiac arrest and the quality of life of the survivors by developing innovative devices for resuscitation. Founded in 2000, the company works closely with leading physicians and paramedics in research and development. The work has led to groundbreaking knowledge about the physiological effects of a cardiac arrest and the significance of quality compressions. The LUCAS Chest Compression System is available for sale in the US, Europe and several other geographies. JOLIFE is based in Sweden, and markets its products through an exclusive distributor agreement. For more information, please visit www.jolife.com and www.lucas-cpr.com or contact: Erik von Schenck, CEO, Jolife AB, cell phone: +46 733 14 74 71.